Recruiting

New dual-target cell therapy versus standard cell therapy for aggressive lymphoma

Plain-English translation of NCT07188558 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing a new cell therapy called (ronde-cel) against two currently approved cell therapies for aggressive B-cell lymphoma that has returned or become resistant to standard chemotherapy. The new treatment is designed to target two different proteins on cancer cells, which may help it work better and last longer in your body. You would be randomly assigned to receive either the new treatment or one of the standard approved options.

Many patients who receive the currently approved cell therapies still experience their cancer coming back, often because cancer cells lose one of the targeted proteins or the immune cells become exhausted. This medication is designed to overcome those problems by targeting two proteins at once, potentially offering a more durable response.

Do you qualify?

You likely qualify if…

you have been diagnosed with a specific type of aggressive B-cell lymphoma (such as diffuse large B-cell lymphoma)
your lymphoma has come back after or stopped responding to first-line chemotherapy that included anti-CD20 antibodies
you have never received CAR T-cell therapy before
you have measurable disease visible on a recent PET scan
you are in generally good health with adequate organ function and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

You likely don't qualify if…

you have received any prior CAR T-cell therapy
your lymphoma is located in the brain or central nervous system
you have an uncontrolled active infection despite antibiotics or other treatment
you have an active autoimmune disease requiring ongoing immunosuppressive therapy
you have had another cancer in the past (unless you have been cancer-free for at least 2 years)

What participation looks like

You would receive a treatment called leukapheresis to collect your immune cells, which are then engineered in a lab and given back to you as a single intravenous infusion after chemotherapy to prepare your body. You would then be followed closely for 3 years with regular visits to monitor how well the treatment works and check for any side effects, with long-term follow-up extending to 15 years.

AI-generated summary from trial data · Aug 11, 2026 · Not medical advice

Trial locations(36 sites)

United States

Banner MD Anderson Cancer Center, Gilbert, Arizona

Honor Health, Scottsdale, Arizona

Mayo Clinic Arizona, Scottsdale, Arizona

University of Arkansas, Little Rock, Arkansas

Cedars-Sinai Medical Center, Los Angeles, California